PackTalk is a blog for the Healthcare Packaging Industry

Sterilization and the FDA Innovation Challenge


Published on November 7, 2019

By now, we are all familiar with the recent discussion around sterilization in the medical device industry. Ethylene oxide or EtO is the most popular sterilization modality in the industry accounting for approximately half of the market. EtO is a colorless gas, and long-term exposure can pose serious health risks. Some US communities located in and around EtO sterilization facilities have become increasingly concerned, ultimately forcing the FDA to take action. 

Good for community members, but potentially problematic for the medical device industry, including hospitals and patients who need the devices impacted by this. To put it bluntly, the FDA is in a bit of a Catch-22 situation with the question becoming: do they allow sterilizers to release harmful gas knowing it may be dangerous, or do they allow a shortage of medical devices that could save lives?

The FDA is currently working with sterilizers to reduce or abate the EtO being released into the atmosphere (99% destruction of EtO is required), while looking into new & innovative ways to sterilize medical devices. EtO has become the most popular form of sterilization for many reasons, with capacity and scalability being a top area of focus. A vaporized hydrogen peroxide sterilizer, for example, is roughly 80 to 100 cubic feet, whereas an EtO sterilizer is about 1500 to 3000 cubic feet.

The good news is that new medical devices can anticipate and prepare for a different sterilization modality. The bad news … that still leaves hundreds of thousands of medical devices on the market today using EtO. The FDA recently issued an innovation challenge to the industry. And while we will do everything we can to support our partners through this, we also look forward to the innovation that will result from this exercise. Any time we are forced to look at our industry through a different lens, resourcefulness and creativity emerge.


 

Jenn Goff
Director, Product Marketing | Oliver Healthcare Packaging

Comments (0)

Related Articles

Eli Lilly Starts Human Study of Potential COVID-19 Antibody Test

June 6, 2020

Companies and research institutions around the world are racing to find a viable treatment for COVID-19, which has already caused ~370,000 deaths worldwide and continues to rise. Eli Lilly recently announced their progress, and are moving into the human study...

Learn More

A Day in the Life of a Packaging Engineer, and the Impact of COVID-19

June 6, 2020

When starting out my career, the biggest attraction, for me, to medical device packaging was the impact it has on the patient. Five years later and as a Senior Packaging Engineer with Alphatec Spine, it’s still what keeps me passionate about the job and it’s...

Learn More

COVID-19 Testing Supply and Capacity May Be Key to Reopening the Economy

June 6, 2020

Since the first confirmed COVID-19 case reported in the United States in late January, the nation has seen more than 1.6 million confirmed cases and approximately 96 thousand deaths. This number has risen higher than anticipated while states have been staying...

Learn More

Stay Informed

To stay up to date on innovative technology and products, as well as industry trends, subscribe to Oliver’s PackTalk blog below.